Key result
NET deficiency in mice elevates mean arterial pressure and heart rate during activity.
Why the study?
Norepinephrine transporter (NET) deficiency is linked to tachycardia and cardiovascular side effects, but its effects on cardiovascular regulation during wakefulness and activity are not fully understood.
Does norepinephrine transporter deficiency alter blood pressure and heart rate in mice during rest and activity?
Does norepinephrine transporter deficiency alter blood pressure and heart rate in mice during rest and activity?
Absolute Event Rate: 122% vs 116%
p-value: p=<0.0001
Norepinephrine transporter deficiency in mice leads to elevated blood pressure and excessive tachycardia, particularly during wakefulness and activity, highlighting the role of NET in modulating peripheral catecholaminergic signaling.
NET deficiency elevates activity-related BP and HR in mice; extends autonomic regulation insights but leaves human translation open.
BACKGROUND: Norepinephrine (NE) is a primary neurotransmitter of central autonomic regulation and sympathetic nerve conduction, and the norepinephrine transporter (NET) is crucial in limiting catecholaminergic signaling. NET is sensitive to antidepressants, cocaine, and amphetamine. NET blockade often is associated with cardiovascular side effects, and NET deficiency is linked to tachycardia in familial orthostatic intolerance. METHODS AND RESULTS: We telemetrically monitored NET-deficient (NET(-/-)) mice to determine the cardiovascular effects of reduced NE reuptake. Mean arterial pressure was elevated in resting NET(-/-) mice compared with NET(+/+) controls (103+/-0.6 versus 99+/-0.4 mm Hg; P<0.01), and corresponding pressures increased to 122+/-0.3 and 116+/-0.3 mm Hg (P<0.0001) with activity. Heart rate was also greater in resting NET(-/-) mice (565+/-5 versus 551+/-3 bpm; P<0.05), and genotypic differences were highly significant during the active phase (640+/-5 versus 607+/-3 bpm; P<0.0001). Conversely, the respiratory rate of resting NET(-/-) mice was dramatically reduced, whereas increases after the day/night shift surpassed those of controls. Plasma catecholamines in NET(-/-) and NET(+/+) mice were as follows: NE, 69+/-8 and 32+/-7; dihydroxyphenylglycol, 2+0.4 and 17+/-3; epinephrine, 15+/-3 and 4+/-0.6; and dopamine, 13+/-4 and 4+/-1 pmol/mL. Catechols in urine, brain, and heart also were determined. CONCLUSIONS: Resting mean arterial pressure and heart rate are maintained at nearly normal levels in NET-deficient mice, most likely as a result of increased central sympathoinhibition. However, sympathetic activation with wakefulness and activity apparently overwhelms central modulation, amplifying peripheral catecholaminergic signaling, particularly in the heart.
No takes yet. Share an insight, caveat, or question.
Keller et al. (2004) studied Norepinephrine transporter deficiency. Norepinephrine transporter (NET) deficiency vs. NET(+/+) controls was evaluated on Mean arterial pressure with activity (p=<0.0001). Norepinephrine transporter-deficient mice exhibited elevated mean arterial pressure (122 vs 116 mm Hg, P<0.0001) and heart rate (640 vs 607 bpm, P<0.0001) during activity compared with controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: